Linked e-resources
Details
Table of Contents
Intro
Foreword
Contents
About the Editor
1: Recent Advances in In Vitro Generation of Mature Cardiomyocytes
1.1 Introduction
1.2 Mature Cardiomyocyte Internal Complexity
1.3 CM Differentiation Protocols
1.3.1 Hormones
1.3.2 Energy Source
1.3.3 Prolonged Culture Period
1.3.4 Cellular Interactions
1.3.5 Biophysical Stimulation
1.3.6 Substrate Stiffness
1.3.7 Micropatterning
1.4 3D Culture System
1.5 Bioprinting
1.6 Microelectrode Cultured CM
1.7 Conclusion and Future Challenges
References
2: Cardiac Reprogramming with Stem Cells: An Advanced Therapeutic Strategy in Advanced Heart Failure
2.1 Introduction
2.2 Advanced Heart Failure: Definition and Contemporary Strategy
2.3 Modality of Action and Targets for Cell Care in Advanced HF
2.4 Cell Therapy in Advanced HF
2.4.1 Induced Pluripotent Stem Cells
2.4.2 Endothelial Progenitor Cells and Bone Marrow Mononuclear Cells
2.4.3 Cardiac Stem Cells
2.4.4 Mesenchymal Stem Cells
2.4.5 Skeletal Myoblasts
2.5 Future Directions for Investigations
2.6 Conclusion
References
3: Induced Pluripotent Stem Cells and Allogeneic Mesenchymal Stem Cell Therapy in Cardiovascular Diseases
3.1 Introduction
3.2 Allogeneic Cell Therapy
3.2.1 Moving Towards Allogeneic Cell Therapy
3.2.2 Cellular Recognition
3.2.3 Production Technology
3.2.4 Preclinical and Clinical Allogeneic Experience
3.2.4.1 Safety
3.2.4.2 Efficacy
3.2.4.3 Perspectives
3.3 Induced Pluripotent Stem Cells
3.3.1 iPSCs and Cardiomyocytes Maturation
3.3.2 iPSCs Maturation
3.3.3 Long QT Syndrome
3.3.4 Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy
3.3.5 Brugada Syndrome
3.3.6 Familial Arrhythmogenic Right Ventricular Dysplasia
3.3.7 Biological Pacemakers
3.3.8 Status of iPSCs in the Treatment of Heart Failure
3.4 Administration Routes for Advanced Therapy Medicinal Products in Patients with Cardiovascular Diseases
3.4.1 Cell/ATMPs Currently Proposed Delivery Routes
3.4.1.1 Peripheral Intravenous Injections
3.4.1.2 Intracoronary Injections
3.4.1.3 Intramyocardial Injections
3.4.1.4 Transendocardial Approach
3.4.1.4.1 Electromechanically-Guided Procedure
3.4.1.4.2 Fluoroscopy-Guided Procedures
3.4.1.5 Transepicardial Approaches
3.4.1.5.1 Surgical Approach
3.4.1.5.2 Minimally Invasive Approach
3.4.1.5.3 Intrapericardial Approach
3.5 Conclusions
References
4: ``Heart Cells ??Derived from Pluripotent Stem Cells and Therapeutic Applications
4.1 Introduction
4.2 Induced Pluripotent Stem Cell Sources
4.3 Cardiomyocytes
4.3.1 iPSC-Derived Cardiomyocyte Differentiation and Manufacturing Protocols
4.3.2 iPSC-Derived Cardiomyocyte Transplantation and Large Animal Studies
4.3.3 iPSC-Derived Cardiomyocyte Transplantation and Clinical Trials
Foreword
Contents
About the Editor
1: Recent Advances in In Vitro Generation of Mature Cardiomyocytes
1.1 Introduction
1.2 Mature Cardiomyocyte Internal Complexity
1.3 CM Differentiation Protocols
1.3.1 Hormones
1.3.2 Energy Source
1.3.3 Prolonged Culture Period
1.3.4 Cellular Interactions
1.3.5 Biophysical Stimulation
1.3.6 Substrate Stiffness
1.3.7 Micropatterning
1.4 3D Culture System
1.5 Bioprinting
1.6 Microelectrode Cultured CM
1.7 Conclusion and Future Challenges
References
2: Cardiac Reprogramming with Stem Cells: An Advanced Therapeutic Strategy in Advanced Heart Failure
2.1 Introduction
2.2 Advanced Heart Failure: Definition and Contemporary Strategy
2.3 Modality of Action and Targets for Cell Care in Advanced HF
2.4 Cell Therapy in Advanced HF
2.4.1 Induced Pluripotent Stem Cells
2.4.2 Endothelial Progenitor Cells and Bone Marrow Mononuclear Cells
2.4.3 Cardiac Stem Cells
2.4.4 Mesenchymal Stem Cells
2.4.5 Skeletal Myoblasts
2.5 Future Directions for Investigations
2.6 Conclusion
References
3: Induced Pluripotent Stem Cells and Allogeneic Mesenchymal Stem Cell Therapy in Cardiovascular Diseases
3.1 Introduction
3.2 Allogeneic Cell Therapy
3.2.1 Moving Towards Allogeneic Cell Therapy
3.2.2 Cellular Recognition
3.2.3 Production Technology
3.2.4 Preclinical and Clinical Allogeneic Experience
3.2.4.1 Safety
3.2.4.2 Efficacy
3.2.4.3 Perspectives
3.3 Induced Pluripotent Stem Cells
3.3.1 iPSCs and Cardiomyocytes Maturation
3.3.2 iPSCs Maturation
3.3.3 Long QT Syndrome
3.3.4 Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy
3.3.5 Brugada Syndrome
3.3.6 Familial Arrhythmogenic Right Ventricular Dysplasia
3.3.7 Biological Pacemakers
3.3.8 Status of iPSCs in the Treatment of Heart Failure
3.4 Administration Routes for Advanced Therapy Medicinal Products in Patients with Cardiovascular Diseases
3.4.1 Cell/ATMPs Currently Proposed Delivery Routes
3.4.1.1 Peripheral Intravenous Injections
3.4.1.2 Intracoronary Injections
3.4.1.3 Intramyocardial Injections
3.4.1.4 Transendocardial Approach
3.4.1.4.1 Electromechanically-Guided Procedure
3.4.1.4.2 Fluoroscopy-Guided Procedures
3.4.1.5 Transepicardial Approaches
3.4.1.5.1 Surgical Approach
3.4.1.5.2 Minimally Invasive Approach
3.4.1.5.3 Intrapericardial Approach
3.5 Conclusions
References
4: ``Heart Cells ??Derived from Pluripotent Stem Cells and Therapeutic Applications
4.1 Introduction
4.2 Induced Pluripotent Stem Cell Sources
4.3 Cardiomyocytes
4.3.1 iPSC-Derived Cardiomyocyte Differentiation and Manufacturing Protocols
4.3.2 iPSC-Derived Cardiomyocyte Transplantation and Large Animal Studies
4.3.3 iPSC-Derived Cardiomyocyte Transplantation and Clinical Trials